Skip to main content

Table 5 The changes of laboratory examination data between pre- and post-TAE status

From: Intended preoperative trans-arterial embolization for large hepatocellular carcinoma: a retrospective cohort study

Variable

 

pre-TAE

n=5 (%)

post-TAE

n=5 (%)

p value

AST (IU/l)

 

73.8 ± 28.0

32.2 ± 13.5

0.017

ALT (IU/l)

 

44.2 ± 20.4

27.8 ± 14.3

0.180

Total Bilirubin (mg/dl)

 

0.74 ± 0.36

0.54 ± 0.29

0.359

Albumin (g/dl)

 

3.80 ± 0.77

3.84 ± 0.15

0.913

PT-INR

 

1.08 ± 0.07

1.08 ± 0.05

0.959

Platelet count (/μl)

 

37.8 ± 14.1

21.9 ± 6.0

0.049

ICG-R15 (%)

 

13.6 ± 2.6

14.9 ± 6.3

0.676

Child-Pugh

A

5 (100.0)

5 (100.0)

0.999

AFP (ng/ml)

 

2907.2 ± 6313.9

20.5 ± 33.2

0.337

AFP-L3 (%)

 

2.5 ± 4.6

3.7 ± 5.3

0.719

PIVKA-II (mAU/ml)

 

43019.0 ± 29839.0

5142.0 ± 10622.0

0.028

  1. Consequent values are expressed as means ± standard errors
  2. TAE trans-arterial embolization, AST aspartate aminotransferase, ALT alanine aminotransferase, PT-INR prothrombin time-international normalized ratio, ICG-R15 indocyanine green retention15, AFP alpha-fetoprotein, AFP-L3 L3 fraction of alpha-fetoprotein, PIVKA-II protein-induced vitamin K absence or antagonist-II